Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Overview

Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response. In general, induction therapy is associated with better outcomes compared to the absence of induction therapy. However, currently used induction agents, some of which are not labeled or indicated for induction therapy in transplantation, have drawbacks related to long-term immune system suppression increasing susceptibility to opportunistic infections or malignancies, and other immune-mediated side effects. An unmet medical need exists for a more specific approach to prevent acute organ rejection, without unnecessarily exposing the patient to non-specific or open-ended immune suppression, which may exacerbate the risks of infections and malignancies. TOL101 is a novel antibody that targets a very specific immune cell type that is critical in the acute organ rejection response. In this two-part study, TOL101 will be evaluated for the prophylaxis of acute organ rejection when used as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus in first time kidney transplant recipients. This study will test the hypothesis that a more specific approach (with TOL101) to prevention of acute organ rejection may provide similar or better efficacy than the currently used induction antibodies (such as Anti-Thymocyte Globulin or Thymoglobulin) while carrying fewer risks in terms of opportunistic infections, malignancies and adverse effects.

Full Title of Study: “A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2013

Interventions

  • Drug: Anti-Thymocyte Globulin
    • 1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
  • Drug: TOL101
    • Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
  • Drug: TOL101
    • Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
  • Drug: Steroids
    • IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
  • Drug: Tacrolimus
    • Oral administration started by 6 days post-transplantation and continued for 6 months
  • Drug: Mycophenolate mofetil (MMF)
    • Oral administration started by Day 1 post-transplantation and continued for 6 months

Arms, Groups and Cohorts

  • Active Comparator: Anti-Thymocyte Globulin
    • Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
  • Experimental: TOL101 (Dose A)
    • TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
  • Experimental: TOL101 (Dose B)
    • TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.

Clinical Trial Outcome Measures

Primary Measures

  • To assess the safety and tolerability of ascending doses of TOL101 and the effectiveness of TOL101 to target and downregulate T cells in patients undergoing first renal transplantation
    • Time Frame: 6 months
    • The following safety parameters will be monitored: Adverse events, standard laboratory safety evaluations (hematology and serum chemistries), symptom constellation indicating cytokine release syndrome, serum concentrations of cytokines and nitric oxide, malignancies, CMV viremia, BKV viremia, EBV viremia and other infections

Secondary Measures

  • The effects of ascending doses of TOL101 on CD3+ T lymphocyte numbers and other immune cell subsets
    • Time Frame: 14 days post-transplant (Part A); 6 months (Part B)
  • The pharmacokinetic (PK) profile of TOL101 in renal transplant recipients and the exposure-response (PK parameter to CD3+ T lymphocyte numbers) relationship over time
    • Time Frame: 14 days post-transplant
  • Biopsy-proven acute organ rejection
    • Time Frame: 6 months
  • Graft survival
    • Time Frame: 6 months
  • Patient survival
    • Time Frame: 6 months
  • Renal function by measured GFR at 6 months post-transplant and urine protein to creatinine ratio at 3 and 6 months post-transplant
    • Time Frame: 6 months
  • Delayed graft function
    • Time Frame: first 7 days post-transplant
  • Immunogenicity of TOL101 by measurement of anti-TOL101 antibodies
    • Time Frame: at 14 and 28 days post-transplant
  • The presence of Donor Specific Antibody at 3 months (Part B only) and 6 months post-transplant
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Recipient of a primary renal transplant from a living or standard criteria cadaveric donor – Male or female 18-60 years of age – Recipient with a PRA < 20% Exclusion Criteria:

  • Previous solid organ transplant – Recipient of HLA-identical kidney allograft transplant – Recipient of an ABO incompatible donor kidney – Known HIV infection or other major infection – History of malignancy within 3 years (excluding treated basal cell or squamous cell carcinoma of the skin) prior to enrollment – History of tuberculosis – Recipient with cardiovascular disease – Treatment with immunosuppressive medications within 1 month prior to enrollment – Known or suspected allergy to mice – Pregnant or lactating – Unable or unwilling to participate in all required study activities for the duration of the study (6 months)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tolera Therapeutics, Inc
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stuart Flechner, MD, Principal Investigator, The Cleveland Clinic

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.